Related Experiment Video
Updated: Feb 14, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
The antitumor mechanism of oclacitinib in canine lymphoma
Miruki Harada1, Sakuya Inanaga1, Masashi Sakurai2,3
1Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, 753-8515, Japan.
Abstract:
Janus kinase (JAK) is a tyrosine kinase that binds to cytokine receptors and regulates transcription through signal transducer and activator of transcription (STAT) phosphorylation. Oclacitinib is a JAK1 inhibitor that is approved for the treatment of canine atopic dermatitis because it inhibits IL-31 signaling. Recent studies suggest clinical remission in dogs with cutaneous lymphoma treated with oclacitinib; however, the underlying mechanisms remain unclear. Its effects on high-grade canine lymphomas beyond cutaneous lymphoma are unknown. In this study, we examined the antitumor mechanism of oclacitinib in canine cutaneous lymphoma and determined its effects on high-grade canine lymphoma cell lines in vitro. EO-1 (cutaneous lymphoma) and eight high-grade lymphoma cell lines were treated with oclacitinib. Growth inhibition, cell death, G0/G1 phase cell cycle arrest, and apoptosis based on caspase-3 activation were observed in five sensitive cell lines. JAK1 and STAT5 phosphorylation was detected in these cells and decreased upon treatment, suggesting a dependence on JAK1/STAT5 signaling. In canine cutaneous lymphoma tissues, JAK1/STAT5 phosphorylation correlated with clinical sensitivity to oclacitinib. Similar phosphorylation profiles were observed in some multicentric and gastrointestinal lymphomas, suggesting broader applicability. Taken together, the results indicate that oclacitinib exerts antitumor effects by inhibiting JAK1/STAT5 signaling. The phosphorylation of these proteins may serve as a biomarker for predicting response to this inhibitor in canine lymphoma.
Insights
Oclacitinib, a Janus kinase (JAK) inhibitor, shows antitumor effects in canine lymphoma by blocking JAK1/STAT5 signaling. This mechanism may predict treatment response in dogs with various lymphoma types.
Area of Science:
- Veterinary Oncology
- Immunology
- Molecular Biology
Background:
- Oclacitinib is a JAK1 inhibitor approved for canine atopic dermatitis.
- Its efficacy and mechanism in canine lymphoma, particularly high-grade types, are not fully understood.
- Previous studies suggest potential benefits in canine cutaneous lymphoma.
Purpose of the Study:
- To investigate the antitumor mechanisms of oclacitinib in canine cutaneous lymphoma.
- To evaluate the effects of oclacitinib on high-grade canine lymphoma cell lines in vitro.
- To determine if JAK1/STAT5 signaling is a key pathway and potential biomarker for oclacitinib response.
Main Methods:
- Treatment of canine cutaneous lymphoma (EO-1) and eight high-grade lymphoma cell lines with oclacitinib.
- Assessment of cell growth inhibition, cell death, cell cycle arrest (G0/G1), and apoptosis (caspase-3 activation).
- Analysis of Janus kinase 1 (JAK1) and signal transducer and activator of transcription 5 (STAT5) phosphorylation levels before and after treatment, and correlation with clinical data.
Main Results:
- Oclacitinib induced growth inhibition, cell death, G0/G1 cell cycle arrest, and apoptosis in five sensitive cell lines.
- Sensitive cell lines exhibited JAK1 and STAT5 phosphorylation, which decreased after oclacitinib treatment, indicating pathway dependence.
- JAK1/STAT5 phosphorylation in canine cutaneous lymphoma tissues correlated with clinical sensitivity, and similar profiles were seen in multicentric and gastrointestinal lymphomas.
Conclusions:
- Oclacitinib exerts antitumor effects in canine lymphoma by inhibiting JAK1/STAT5 signaling.
- JAK1/STAT5 phosphorylation can serve as a predictive biomarker for oclacitinib response in canine lymphoma.
- The findings suggest broader applicability of oclacitinib beyond cutaneous lymphoma.
Related Concept Videos
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Mechanical Protein Functions
Mechanism of Conjugation
Mechanism of Angiogenesis
An Introduction to Mechanics
According to records, the history of mechanics starts with Aristotle (384–322 BC). He related mechanics to physical theory, aiming for a universal synthesis.
Newton defined mechanics as the branch of physical science that...
Mechanical Systems

